New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


It’s Crucial That Patients Identify The Mutations Driving Their Lung Cancers

by CURE Today Staff It's crucial that patients identify mutations driving their lung cancers. There are a host of treatments available for non-small cell lung cancer (NSCLC) these days, and for patients, perhaps the most crucial step in c…


UCLA Lung Cancer Screening and Early Detection

  Lung cancer is by far the most common cancer killer of both men and women in the United States. Among individuals with lung cancer, survival rates after diagnosis are very low. This is because most lung cancers are diagnosed only …


Active Therapeutic Thoracic Trials – December 2017

The Ohio State University Cancer Research Center was established in 1973 and received National Cancer Institute designation in April 1976 as a comprehensive cancer center (OSUCCC). The patient care arm of the OSUCCC is the Arthur G. James C…


FDA grants approval for in vitro diagnostic

Detecting genetic mutations in vitro: On November 30, 2017, the Food and Drug Administration granted marketing approval to the FoundationOne CDx (F1CDx, Foundation Medicine, Inc.), a next generation sequencing (NGS) based in vitro diagn…


Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

from OncLive Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with a…

Read More